Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318551 | 1.00 | KIF11 (0.36) | KIF11SHMT1PPARACYP3A4PTPN1 | |
| SCHEMBL6324965 | 0.93 | RORB (0.37) | KIF11SHMT1 | |
| SCHEMBL6324968 | 0.93 | RORB (0.37) | KIF11SHMT1 | |
| SCHEMBL6317258 | 0.93 | CYP3A4 (0.39) | KIF11SHMT1CYP3A4PTPN1ADAMTS5 | |
| SCHEMBL6318056 | 0.90 | KIF11 (0.37) | KIF11SHMT1PPARACYP3A4PTPN1 | |
| SCHEMBL6318059 | 0.90 | KIF11 (0.37) | KIF11SHMT1PPARACYP3A4PTPN1 | |
| SCHEMBL6317861 | 0.90 | PPARA (0.38) | KIF11SHMT1PPARAPTPN1ADAMTS5 | |
| SCHEMBL6317863 | 0.90 | PPARA (0.38) | KIF11SHMT1PPARAPTPN1ADAMTS5 | |
| SCHEMBL6324953 | 0.89 | KIF11 (0.35) | KIF11TMEM97SIGMAR1 | |
| SCHEMBL6318887 | 0.89 | RORB (0.38) | KIF11SHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | KIF11 2199/4885SHMT1 2213/4885PPARA 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.